Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Centanafadine in binge eating disorder
NCT05113953Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Dec 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of centanafadine in binge eating disorder (BED) (3 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Change From Baseline in Number of Binge Eating Days Per Week at 8 weeks. Started Dec 2021; status: completed.
02
Drugs
centanafadine
03
Conditions
binge eating disorder (BED)
Beyond the preview
Go deeper on NCT05113953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05113953.